Healthcare Industry News: Cardiac Ablation
News Release - January 12, 2010
The Methodist DeBakey Heart & Vascular Center Purchases Third Sensei X Robotic Catheter System; Opens New Vascular Research Laboratory
Methodist Selected as a Hansen Medical Center of Excellence for Sensei X Robotic Catheter PlatformMOUNTAIN VIEW, CA--(HSMN NewsFeed) - Hansen Medical, Inc. (NASDAQ:HNSN ), the global leader in flexible medical robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced that the Methodist DeBakey Heart & Vascular Center in Houston has purchased its third Sensei X Robotic Catheter System.
Methodist has also opened a new Vascular Research Laboratory, where physicians will use the Sensei X and other flexible robotics technology to research pre-clinical capabilities in vascular surgery including procedure targets in the peripheral vasculature and the abdominal and thoracic aorta, as well as developing procedures in structural heart disease.
In addition, Hansen Medical selected Methodist to be a Center of Excellence where physicians from around the globe will have the opportunity to be trained on flexible robotics with world-renowned physicians in a high-volume electrophysiology lab. The new Center of Excellence commenced operation in late December 2009.
"The Methodist DeBakey Heart & Vascular Center is delighted to be the first center in the world with three Sensei X robots," said Alan B. Lumsden, M.D., medical director of the Methodist DeBakey Heart & Vascular Center and chair of the department of cardiovascular surgery at The Methodist Hospital. "Because of the close collaboration between cardiologists and cardiovascular surgeons in our center, we have rapidly shared both our skills and the medical robotic technology between electrophysiology and vascular surgery. We view the convergence of flexible catheter robotics and advanced imaging systems as the new frontier in performing endovascular procedures.
"Furthermore, the Methodist Institute for Technology Innovation and Education (MITIE(TM)) provides the ideal venue for training and development of new procedures," continued Dr. Lumsden.
According to Dr. Valderrabano, chief of the division of cardiac electrophysiology at The Methodist Hospital, "Flexible robotics and the Sensei X can revolutionize how cardiac arrhythmia procedures are performed, yet these techniques have remained limited often because other physicians are not aware of what robotics offers. Close contact between physicians of different specialties has the potential to lead to improved procedure outcomes by sharing techniques and combining expertise."
Hansen Medical will recognize revenue on the third Sensei X system purchased by Methodist following the completion of any obligations under the Center of Excellence and research agreements to be entered into with Methodist.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, Calif., develops products and technology using robotics for the accurate positioning, manipulation, and control of catheters and catheter-based technologies. Its first product, the Sensei Robotic Catheter system, is a robotic navigation system that enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. The Sensei system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data and was cleared by the U.S. Food and Drug Administration (FDA) in May 2007 for manipulation and control of certain mapping catheters in Electrophysiology (EP) procedures. The safety and effectiveness of the Sensei system for use with Cardiac Ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. In the European Union, the Sensei system is cleared for use during EP procedures, such as guiding catheters in the treatment of AF. Additional information can be found at www.hansenmedical.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks, uncertainties, assumptions, and other factors, which, if they do not materialize or prove correct, could cause Hansen's results to differ materially from those expressed or implied, by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including, statements containing the words "plan," "expects," "believes," "goal," "estimate," "may" and similar words. Hansen intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements about the potential effects of flexible robotic technology on the vascular and other procedures. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, product development risks, potential safety and regulatory issues that could delay approvals, and the scope and validity of intellectual property rights applicable to products being developed. These and other risks are described in greater detail under the heading "Risk Factors" contained in our periodic SEC filings, including our Quarterly Report on Form 10-Q filed with the SEC on November 16, 2009. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
"Hansen Medical", "Hansen Medical Heart Design", "Hansen Medical & Heart Design", and "Sensei" are registered trademarks and "Artisan" is a trademark of Hansen Medical, Inc., in the United States and other countries.
Source: Hansen Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
